What's hot

View all perspectives
What's Hot

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay

Watch video →

RheumNow Rheumatology Roundup: Drs. Kavanaugh and Cush

Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021.    

Watch video →

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting

RheumNow TNFi faculty convened to discuss several TNFi-related abstracts presented at ACR 21. Panelists: Drs. Aurelie Najm, Janet Pope, David Liew, Eric Dein and Swetha Alexander. 

Watch video →

Spondyloarthritis Panel Discussion: ACR21 Meeting

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood. Abstracts discussed include #0562, #1919, #0907, #0364 and #0919

Watch video →

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.

Watch video →

Diagnosing (Bad) VEXAS: The Experts Speak Drs. Beck and Ferrada

Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.

Watch video →

Pediatric Psoriatic Arthritis: Dr. Eric Ruderman

Dr. Ruderman discusses abstracts #1424 presented at the ACR21 annual meeting.

Watch video →

Urine Proteome Advances: What Do They Mean? Dr. Michelle Petri

Dr. Petri reviews abstracts #1422 and #1936, presented at the ACR21 annual meeting.

Watch video →

ACR21 Day 3 Recap: Polypharmacy, New Lupus Drugs, VEXAS, Safety Data

Blurb: Drs. Jack Cush and the RheumNow Faculty Drs. Akhil Sood, Antoni Chan, Olga Petryna and Eric Dein, discuss highlights from Day 3 (Monday) at the ACR21 annual meeting. Abstracts include #1367, #1044, #1444, #1083 and more.

Watch video →

Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles

Dr. Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.

Watch video →

Predictors of TNF Response with Drs. Pope, Dein and Liew

Drs. Janet Pope, David Liew and Eric Dein discuss TNF data presented at the ACR21 annual meeting, including abstracts #1251, #1442, #1448.

Watch video →

Caring for the Older Patient with Rheumatic Disease: Drs. Makris, Yung and Dao

Drs. Kathryn Dao, Una Makris and Raymond Yung discuss the field of geriatric rheumatology and caring for the older patient with rheumatic disease.

Watch video →

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares

  Drs. Jack Cush, Yuz Yusof, Bella Mehta, Olga Petryna and Rachel Tate review autoinflammatory data presented at the ACR21 annual meeting, including abstracts #1100, #1062, #1426, #0252, #0195, and #1083.

Watch video →

FDA Session Review: Dr. Arthur Kavanaugh

Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.

Watch video →

The Respiratory Tract and RA with Drs. Sparks, McDermott and Kronzer

Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the ACR21 annual meeting.

Watch video →

Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush

Dr. Cush reviews poster #1100 presented at the ACR21 annual meeting.

Watch video →

Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri

Dr. Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the ACR21 annual meeting.

Watch video →

ACR21 Day 2 Recap: CV Risk, Tapering in SpA, Microbiome in PsA, Vit D

Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 (Sunday) at the ACR21 Virtual meeting.

Watch video →
      RT @DrMiniDey: #ACR21 Plenary Abs#0457 @alhkim #COVaRiPAD study:
      👉Patients with inflammatory diseases on #immunosuppr

      Mrinalini Dey DrMiniDey

      4 years ago
      #ACR21 Plenary Abs#0457 @alhkim #COVaRiPAD study: 👉Patients with inflammatory diseases on #immunosuppression have impaired #SARSCoV2 immunity post-vaccine 👉#Steroids, MMF & B cell depletion therapy more severely affect responses 👉https://t.co/7qTABcpm0h @RheumNow #ACRBest https://t.co/EfuHjh3vw5
      RT @DrPetryna: Abst0254 #ACR21 @RheumNow CARRA SJIA cohort defines factors associated with medication free remission for

      Olga Petryna DrPetryna

      4 years ago
      Abst0254 #ACR21 @RheumNow CARRA SJIA cohort defines factors associated with medication free remission for ≥6 month-period: younger age, normal CRP levels & shorter time btw diagnosis and start of Rx. none of pts who developed MAS (3.9%) able to d/c Rx for ≥6 months
      RT @drdavidliew: COVID-19 mRNA vaccination immunogenicity
      (vs immunocompetent):

      TNFi: 2.3x reduction
      JAKi: 2.6x
      AZA: 3.

      David Liew drdavidliew

      4 years ago
      COVID-19 mRNA vaccination immunogenicity (vs immunocompetent): TNFi: 2.3x reduction JAKi: 2.6x AZA: 3.5x MTX: 4.4x steroids: 9x (but confounded by other meds) MMF/MPA: 21x B cell depleting: 57.7x (but 6m gap probably helps) amazing work led by @alhkim #ACR21 ABST0457 @RheumNow https://t.co/cl5vBpNzvQ
      RT @KDAO2011: Dr. @AlHKim on COVaRiPAD data:
      274 pts chronic inflam dz (RA/SLE/IBD/SpA/MS/SS,/Vasculitis) vs 53 control

      TheDaoIndex KDAO2011

      4 years ago
      Dr. @AlHKim on COVaRiPAD data: 274 pts chronic inflam dz (RA/SLE/IBD/SpA/MS/SS,/Vasculitis) vs 53 control 👉90% Ab+ response (⬇️3.4X titer) 👉MMF⬇️21X 👉MTX⬇️4.4X 👉AZA ⬇️3.5X 👉BCDT⬇️ 57.7X 👉JAKi ⬇️2.6 X 👉GCs⬇️9X 👉TNFi impaired neutralization delta #ACR21 #plenary @rheumnow https://t.co/b0DgLjDi6E
      RT @AurelieRheumo: Provocative study in pre-RA. SC Abatacept in patients with pre-clinical RA can:
      -improvement MRI infl

      Aurelie Najm AurelieRheumo

      4 years ago
      Provocative study in pre-RA. SC Abatacept in patients with pre-clinical RA can: -improvement MRI inflammation -⬇️evolution to clinical RA at 6 months -No new safety signal Yes, but we need longer term follow-up and an estimation of NNT. #OP0505 @Rheumnow #ACR2021 https://t.co/2P1Yk3IyeR
      RT @synovialjoints: New treatments in #psoriaticarthritis Brepocitinib TYK 2/JAK 1 inhibitor had superior efficacy vs PB

      Dr. Antoni Chan synovialjoints

      4 years ago
      New treatments in #psoriaticarthritis Brepocitinib TYK 2/JAK 1 inhibitor had superior efficacy vs PBO in active PsA at Week 16, with improvements in more refractory domains over 52 weeks. Safety consistent with other JAKi @RheumNow #ACR21 Abstr#0488 https://t.co/ugsV7uRwro
      RT @Yuz6Yusof: #ACR21 #Abstr0456 How can we explain cognitive impairment in #lupus? Using f- and DCE-MRI, a study showed

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago
      #ACR21 #Abstr0456 How can we explain cognitive impairment in #lupus? Using f- and DCE-MRI, a study showed: 💠Abnormalities in brain functional connectivity 💠Extensive Blood-Brain Barrier leakage (BBB) BBB could be a future target @RheumNow https://t.co/KLeWfbQUQ0 https://t.co/ibNvBUWlMK
      Polyautoimmunity: axSpA and Familial Mediterranean Fever by Dr. Rachel Tate ( @uptoTate )

      Mysteries behind polyautoimm

      Dr. John Cush RheumNow

      4 years ago
      Polyautoimmunity: axSpA and Familial Mediterranean Fever by Dr. Rachel Tate ( @uptoTate ) Mysteries behind polyautoimmunity have confounded rheumatologists for decades. One such association, the co-existence of FMF and axSpA, remains rare. https://t.co/GbU1ikeyQw #ACR21 https://t.co/dRd6yxjieS
      RT @alhkim: So what’s interesting is that type I IFNs actually tighten the BBB. Is this dysfunctional in SLE? Or does

      Alfred Kim alhkim

      4 years ago
      So what’s interesting is that type I IFNs actually tighten the BBB. Is this dysfunctional in SLE? Or does this argue that CI does not correlate with SLE disease activity perhaps? #ACR21 #ACRAmbassador https://t.co/y5x2k3NQFi
      COVaRiPad study - Immunosuppression affects COVID-19 vax Ab levels. 247 pts, 90% seroconverted but @ reduced (3.4 fold)

      Dr. John Cush RheumNow

      4 years ago
      COVaRiPad study - Immunosuppression affects COVID-19 vax Ab levels. 247 pts, 90% seroconverted but @ reduced (3.4 fold) titers. Lowest w/ MMF (21x) and B cell Rx vs MTX/AZA (3-4x). Pts on B cell therapy should wait 6 mos to recv vax #ACR21 Abstr# 0457 https://t.co/1gkCsJSDBk
      RT @drdavidliew: Why is lupus nephritis mortality trending up in the US, in contrast to overall SLE mortality?

      Race mat

      David Liew drdavidliew

      4 years ago
      Why is lupus nephritis mortality trending up in the US, in contrast to overall SLE mortality? Race matters Urban location can make things worse I'm outside looking in but hope it's not too bold to say disparities affect whether you live or die from LN #ACR21 ABST0454 @RheumNow https://t.co/wmB9l9fFTT
      RT @RichardPAConway: Dr De Miguel on subclinical large vessel vasculitis in PMR. US assessment. 22% had subclinical GCA.

      Richard Conway RichardPAConway

      4 years ago
      Dr De Miguel on subclinical large vessel vasculitis in PMR. US assessment. 22% had subclinical GCA. 90% LVV, 10% cranial GCA. Abstr#0466 #ACR21 @RheumNow https://t.co/PDCynMAigi
      RT @swethaann23: #ACR21 #ACRbest @RheumNow
      Abst#0366 by Garrido-Cumbrera et al. looked at shows that three out of four

      swethaann23 swethaann23

      4 years ago
      #ACR21 #ACRbest @RheumNow Abst#0366 by Garrido-Cumbrera et al. looked at shows that three out of four European axSpA patients have difficulty in finding a job.
      RT @doctorRBC: Interesting study on immune cell profiling in PsA pts
      ⭐️variability in T cell sub-populations in PsA

      Robert B Chao, MD doctorRBC

      4 years ago
      Interesting study on immune cell profiling in PsA pts ⭐️variability in T cell sub-populations in PsA pts ⭐️no difference in lymphocyte cell populations before/after therapy Abs#0056 https://t.co/16PYxaxT2S #ACR21 @RheumNow https://t.co/dWaJr7hJ1p
      RT @uptoTate: T2T in AxSpA? ASDAS-qCRP & ASDAS-CRP showed an almost perfect agreement w/ regard to dz activity categ

      Dr. Rachel Tate uptoTate

      4 years ago
      T2T in AxSpA? ASDAS-qCRP & ASDAS-CRP showed an almost perfect agreement w/ regard to dz activity categories (96%.) Quick ASDAS-qCRP can be used in real time to make clinical decisions. Abs 0374 #ACR21 #RheumNow @RheumNow https://t.co/opOyedQUaZ https://t.co/aeUEsW9HsX

      Podcasts

      • Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie 00:20:18
      • Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao 00:20:26
      • The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell 00:35:26

      Catch up on Conference Podcasts

      ×